The review concluded that there was insufficient evidence of a secondary preventive effect of omega-3 fatty acid supplements against overall cardiovascular events among patients with a history of cardiovascular disease. The authors' conclusions reflected the evidence available and appear likely to be reliable.
Where reported, mean age of participants was 63.4 years and 79% were male. Included patient groups were those with stable coronary heart disease, recent myocardial infarction, implanted cardioverter defibrillators, congestive heart failure and other cardiovascular diseases. Daily doses of eicosapentaenoic acid or docosahexaenoic acid ranged from 0.4g to 4.8g. Follow-up ranged from 1.0 to 4.7 years. Placebo groups received vegetable oils, mixed fatty oil and other "inert" or poorly defined substances.
Two reviewers independently selected studies for inclusion. Disagreements were resolved by discussion or by a third reviewer.
Assessment of study quality
Study quality was evaluated using the Jadad scale of randomisation, blinding and withdrawals/drop-outs. The maximum possible score was 5 points.
The authors did not state how many reviewers performed the quality assessment.
Data extraction
Event data for intention-to-treat populations were extracted in order to calculate relative risks (RR) with 95% confidence intervals (CI).
The authors did not state how many reviewers extracted data.
Methods of synthesis
Meta-analyses were performed to calculate pooled relative risks (RRs) with 95% CIs, using a random-effects model. Heterogeneity was assessed using the Ι² statistic (Ι²>50% indicated substantial heterogeneity). Publication bias was assessed using a funnel plot and the Egger test. Subgroup analyses investigated the effect of history (type) of cardiovascular disease, geographic area (inland versus coastal), duration of treatment (less than two years versus two years or more), dosage (<1.7 versus ≥1.7g/day), use of fish oil supplementation only as treatment, type of placebo
